MET097 for Diabesity
(VESPER-2 Trial)
Trial Summary
What is the purpose of this trial?
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should have stable therapy for at least 30 days before the trial, which suggests you may continue your current treatment if it's stable.
What data supports the effectiveness of the drug MET097 for Diabesity?
Is MET097 safe for humans?
Metformin, which may be similar to MET097, is generally considered safe for treating type 2 diabetes. It has been shown to improve blood sugar control and has beneficial effects on heart health, blood pressure, and weight. However, like any medication, it can have side effects, so it's important to discuss with a doctor.46789
How does the drug MET097 differ from other treatments for diabesity?
Eligibility Criteria
Adults with obesity or overweight and type 2 diabetes mellitus (T2DM) are eligible for this trial. Participants must be able to receive weekly subcutaneous injections for 28 weeks. Specific inclusion and exclusion criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MET097 or placebo via subcutaneous injection once weekly
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MET097
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metsera
Lead Sponsor